RxDoctor Payments DataLook up a doctor →

Olga Fedorenko

Family · Coventry, RINPI 1669855029

Payments from drug & device makers

$24,136in general payments, 2019–2025

Across 838 payments — averaging $28.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$2K
  • AbbVie$2K
  • Novo Nordisk$2K
  • Lundbeck LLC$1K
  • Amgen$1K
  • plus $13K from 48 others

What the payments were for

  • Food & beverage$24,136100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,136 in reported general payments places this provider in the 95th percentile of 457 family providers in Rhode Island.

See all family providers in Rhode Island

Medicare billing

Part B allowed, 2024
$15,232
Medicare patients
46
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$16,830
EliquisApixaban25$13,694
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$12,882
JardianceEmpagliflozin15$8,835
FarxigaDapagliflozin Propanediol15$8,438
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog14$6,891
Metformin Er OsmoticMetformin Hcl11$5,968
Memantine Hcl ErMemantine Hcl11$3,882
Atorvastatin Calcium131$1,661
Albuterol Sulfate HfaAlbuterol Sulfate58$1,451
Levothyroxine Sodium82$1,031
Omeprazole61$975
Losartan Potassium97$845
SynthroidLevothyroxine Sodium11$730
Mirtazapine21$713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Farxiga$2,727$25,26842 claims
PfizerEliquis$1,280$13,69425 claims
GSKTrelegy Ellipta$2,189$12,88220 claims
Boehringer IngelheimJardiance$1,048$8,83515 claims
AbbVieSynthroid$1,910$73011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 457 family providers in Rhode Island.

Other family in Coventry

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →